The ABCA1-efferocytosis axis: A new strategy to protect against atherosclerosis

Area of Science:

• Cardiovascular Biology
• Cellular Biology
• Immunology

Background:

• Atherosclerosis, driven by lipid accumulation and inflammation, is a primary cause of coronary heart disease (CHD) and myocardial infarction (MI).
• Efferocytosis, the clearance of apoptotic cells, is critical for resolving inflammation and suppressing atherosclerosis.
• ATP-binding cassette transporter A1 (ABCA1) is essential for reverse cholesterol transport (RCT) and HDL-C generation.

Purpose of the Study:

• To review the role and mechanism of ABCA1 in efferocytosis.
• To highlight new insights into the ABCA1-efferocytosis axis.
• To explore the potential of the ABCA1-efferocytosis axis as a novel therapeutic target for atherosclerosis.

Main Methods:

• Literature review focusing on the molecular mechanisms of ABCA1 in efferocytosis.
• Analysis of ABCA1's regulation of 'find-me' and 'eat-me' ligands.
• Examination of feedback loops involving ABCA1, inflammatory cytokines, and efferocytosis ligands.

Main Results:

• ABCA1 not only mediates cholesterol efflux but also actively promotes efferocytosis.
• ABCA1 regulates the release of 'find-me' ligands (e.g., LPC) and the exposure/release of 'eat-me' ligands (e.g., PtdSer, ANXA1, ANXA5, MEGF10, GULP1).
• ABCA1 shares mechanistic similarities with TG2 and homology with ABCA7, both involved in efferocytosis.

Conclusions:

• ABCA1 acts as a central regulator, linking cholesterol efflux and apoptotic cell clearance.
• The ABCA1-efferocytosis axis presents a promising novel therapeutic target for atherosclerosis.
• Further research into ABCA1's multifaceted role could lead to new treatments for cardiovascular diseases.